Kornimate/medical-research-clean huggingface dataset:
real world prostate cancer registry

Conditions: Prostate Cancer

Summary: prostate cancer is the most common cancer diagnosed in men in the usa with 268,490 cases diagnosed in 2022 constituting 27% of male cancers and 34,500 deaths (11%) occurred in same year.1 prostate cancer is a very heterogeneous disease that has different presentations, molecular and pathological features, stages, and disease biology. the treatment options are dependent on the disease stage, its features, and the patient's condition and preferences. the disease outcome also varies significantly due to the previous heterogeneity of the features in addition to other social determinants of health. therefore, it is critical to obtain real-world data that reflects the actual patterns of prostate cancer presentation, work up, management, and outcome. real world prostate cancer registry (rwpcr) aims at compiling real world data from patients presented with prostate cancer in the tristate area. the data collection will be prospective and longitudinal including patients' demographics and disease characteristics, work up, management, and outcome.

real world prostate cancer registry (rwpcr) aims at compiling real world data from patients presented with prostate cancer in the tristate area. the data collection will be prospective and longitudinal including patients' demographics and disease characteristics, work up, management, and outcome. primary objectives: describing the patterns of prostate cancer presentation, management, and outcome in the studied population identify any impact of the compiled variables on treatment selection, work up and outcome. secondary objectives: identify any gaps and variations in the delivery of care, challenges and needs to optimize management of the disease and improve patient's outcome. improve awareness and facilitate enrollment into clinical trials and research studies. data will be collected directly from patients. this data will be collected over 10 years with three years of enrollment and seven years of follow-up. patients provide e-consent and then get login credentials to complete the e-forms which can be edited and updated by the patient. 6 monthly reminders will be sent to the patients to complete 6 monthly follow-ups research staff may contact patients to offer opportunities to participate in clinical trials if eligible. a gift card will be provided to the patient for the initial survey submission. a gift card will also be provided to the patient for each 6 month follow up submission.

Eligibility criteria:
inclusion criteria: all patients with pathologically confirmed primary prostate cancer diagnosis since january 1st, 2023 acceptance to sign the consent form 18 years old or older resident of ohio, kentucky or indiana exclusion criteria: having diagnosis of other cancer except squamous cell cancer of the skin refusal to sign a consent form.
usefulness of gi-genius in fit-based colorectal cancer screening program.

Conditions: Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Colonic Polyp; Colorectal Cancer; Adenoma Colon; Serrated Adenoma; Serrated Polyp

Summary: deep learning technology has an increasing role in medical image applications and, recently, an artificial intelligence device has been developed and commercialized by medtronic for identification of polyps during colonoscopy (gi-genius). this kind of computer-aided detection (cade) devices have demonstrated its ability for improving polyp detection rate (pdr) and the adenoma detection rate (adr). however, this increase in pdr and adr is mainly made at the expense of small polyps and non advanced adenomas. colonoscopies after a positive fecal immunochemical test (fit) could be the scenario with a higher prevalence of advanced lesions which could be the ideal situation for demonstrating if these cade systems are able also to increase the detection of advanced lesions and which kind of advanced lesions are these systems able to detect. the cadillac study will randomize individuals within the population-based spanish colorectal cancer screening program to receive a colonoscopy where the endoscopist is assisted by the gi-genius device or to receive a standard colonoscopy. if our results are positive, that could suppose a big step forward for cade devices, in terms of definitive demonstration of being of help for efectively identify also advanced lesions.


Eligibility criteria:
inclusion criteria: * individuals with a positive result in fecal immunochemical test within the population-based colorectal cancer screening program. * complete colonoscopy with cecal intubation. * inform consent signed. exclusion criteria: * personal history of colorectal cancer. * family history of colorectal cancer: ≥2 fdr or ≥1 fdr diagnosed before 50 years of age. * family history of hereditary colorectal cancer syndromes: lynch syndrome, fap, etc. * personal history of inflammatory bowel disease. * terminal illness. * personal history of total proctocolectomy.
protein kinase 2 (hipk2) polymorphisms on rs2058265, rs6464214, and rs7456421

Conditions: Kidney Stone

Summary: in the present study investigators aimed to investigate whether homeodomain interacting protein kinase 2 (hipk2) polymorphism is associated with renal stone formation in turkish population or not. one hundred and twenty nine participants with calcium nephrolithiasis and 67 sex and age-matched healthy controls were enrolled in this study. for analysis of hipk2 polymorphism, the real-time pcr amplification was performed in a final volume of 20μl reaction mixture, including 10 ng of genomic dna, 5 µl of taqman® universal pcr master mix, and 0.5 µl of 40x taqman® assay. the rotor-gene q series software version q 2.3.1 (rotor-gene q series, ziagen) was used for allelic discrimination. chi square test was utilized to compare the differences of the genotype and allele frequencies between patients and controls.

kidney stone incidence depends on geographical, climatic, ethnic, dietary and genetic factors. thus the prevalence rates for urinary stones change from 1% to 20%. 1,2 genetic polymorphism also causes nephrolithiasis. the most known polymorphic genes are the calcium-sensing receptor (casr), vitamin d receptor (vdr), and matrix gla protein (mgp), plasminogen activator, urokinase (plau). 3,4 furthermore, the concordance rate of the stone disease in monozygotic twins is substantially higher than in dizygotic ones (32.4% vs. 17.3%) demonstrating that genetic factors play a vital role in the formation of nephrolithiasis. 5 homeodomain interacting protein kinase 2 (hipk2) has been shown to be a new androgen receptor regulator. hipk2 and androgen were demonstrated to mediate kidney tubular epithelial cell injury and apoptosis. informations on hipk2 polymorphism about renal stone formation are newfound and inconclusive. therefore, in this study, authors aimed to investigate whether hipk2 polymorphism is associated with renal stone formation in turkish population or not.

Eligibility criteria:
inclusion criteria: patients with nephrolithiasis exclusion criteria: * patients had a history of chronic urinary tract infection * renal failure * gastrointestinal diseases * increased levels of vitamin d * sarcoidosis * primary hyperoxaluria * polycystic kidney disease, gout, renal tubular acidosis, primary and secondary hyperparathyroidism.

Keywords: ksd hipk2 gene polymorphism
explicit assessment of thromboembolic risk and prophylaxis for medical patients in switzerland

Conditions: Venous Thromboembolism

Summary: until now, no risk assessment model informing about the need of thromboprophylaxis in patients admitted for an acute medical event has been validated. the goal of this project is to indirectly validate a model developed in geneva by a non -interventional study involving the collection of patient characteristics during the hospitalization and a 3-month follow-up. these data will allow for the determination of the patient's risk, according to the geneva model, and its validity, according the actual thrombo-embolic events, corrected for the thromboprophylaxis received. the project is multicentric in switzerland (5-10 centers) and should involve about 1000 patients. first amendment (may 2011) : we have obtained the irb approval for collecting data from patients who die during their hospital stay and for whom informed consent is not be possible to obtain.


Eligibility criteria:
inclusion criteria: * patients admitted (minimal stay \>24 hours) to medical hospital wards * age ≥18 years * ability to give an informed consent, as informed by the physicians in charge of the patient exclusion criteria: * patients admitted to non-medical hospital wards * patients with therapeutic anticoagulation at hospital admission * patients admitted for a disease requiring therapeutic anticoagulation (mte or other) * patients unable to give an informed consent, as informed by the physicians in charge of the patient * patients without signed informed consent * patients already included in this study
helicobacter pylori empiric treatment in ulcer bleeding

Conditions: Peptic Ulcer Hemorrhage

Summary: the goal of the study is to compare the effectiveness of empirical helicobacter pylori treatment compared with treatment depending on diagnostic tests for helicobacter pylori in patients with upper gastrointestinal bleeding due to peptic ulcer. main hypothesis is that empirical treatment will reduce the number of patients lost to follow-up thus improving the cure rates of hp infection.


Eligibility criteria:
inclusion criteria: * patients older than 18. * informed consent signed. * diagnosis of no variceal upper gastrointestinal bleeding secondary to a duodenal ulcer, erosive duodenitis or gastric ulcer. * life expectancy longer than 6 months. * able to attend further clinical controls. * absence of the following exclusion criteria. exclusion criteria: * previous eradication treatment. * use of antibiotics 2 weeks prior to inclusion. * need for antisecretor treatment that cannot be stopped to perform the breath test. * pregnancy or breastfeeding.

Keywords: helicobacter pylori treatment upper gastrointestinal bleeding
bryostatin 1 in treating patients with recurrent or refractory hodgkin's disease

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of bryostatin 1 in treating patients who have recurrent or refractory hodgkin's disease.

objectives: i. determine the response rate in patients with recurrent or refractory hodgkin's disease treated with bryostatin 1. ii. determine qualitative and quantitative toxicities of bryostatin 1 in these patients. iii. determine duration of response and survival in these patients. outline: patients receive bryostatin 1 by continuous iv infusion over 72 hours. courses repeat every 14 days in the absence of disease progression or unacceptable toxicity for at least 4 courses. patients who achieve complete response (cr) are treated with 4 additional courses beyond cr. projected accrual: a total of 14-27 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: diagnosis of recurrent or refractory hodgkin's disease measurable disease must have failed the following regimens: mechlorethamine, vincristine, procarbazine, and prednisone (mopp) and doxorubicin, bleomycin, vinblastine, and dacarbazine (abvd) may have undergone either bone marrow or peripheral blood stem cell transplant must not be eligible for standard treatment (high intensity therapy with peripheral blood stem cell or bone marrow transplant) or higher priority protocol patient characteristics: age: 18 and over performance status: zubrod 0-2 life expectancy: at least 12 weeks hematopoietic: absolute neutrophil count (anc) at least 1,000/mm3 (at least 500/mm3 if extensive bone marrow involvement) platelets at least 75,000/mm3 (at least 50,000/mm3 if extensive bone marrow involvement) hepatic: bilirubin less than 1.5 mg/dl alt and ast less than 2.5 times upper limit of normal renal: creatinine no greater than 1.5 mg/dl or creatinine clearance at least 60 ml/min other: not pregnant or nursing fertile patients must use effective contraception during and for 2 months after study prior concurrent therapy: biologic therapy: see disease characteristics chemotherapy: see disease characteristics at least 4 weeks since prior chemotherapy (8 weeks since mitomycin or nitrosoureas) and recovered endocrine therapy: no concurrent steroids radiotherapy: at least 4 weeks since prior radiotherapy surgery: not specified

Keywords: recurrent adult hodgkin lymphoma
prognostic role of la strain in acute myocardial infarction

Conditions: Atrial Fibrillation; Myocardial Infarction, Acute; Stroke Ischemic; Mortality

Summary: this is a single-center retrospective observational study in which we consecutively selected patients diagnosed with acute myocardial infarction from september 2019 to march 2024 at the affiliated hospital of xuzhou medical university. inclusion criteria: 1. cmr was completed during all hospitalizations; 2. complete clinical data; 3. received continuous cardiac monitoring during hospitalization. exclusion criteria: 1. unclear or non-compliant cmr images; 2. previous history of myocardial infarction; 3. malignant tumors diseases. dedicated cardiovascular imaging software cvi42 (cvi42® version 5.13.5, circle cardiovascular imaging, canada) was used for image analysis. la strain was obtained by cardiac mri feature tracking. patient prognosis was obtained through chart notes and telephone follow-up. major events included atrial fibrillation, ischemic stroke, and all-cause mortality.


Eligibility criteria:
inclusion criteria: * 1.cmr was completed during all hospitalizations; 2. complete clinical data; 3. received continuous cardiac monitoring during hospitalization. exclusion criteria: * 1.unclear or non-compliant cmr images; 2. previous history of myocardial infarction; 3. malignant tumors diseases.

Keywords: cardiac magnetic resonance myocardial infarction atrial fibrillation ischemic stroke
chromosomal damage in type 2 diabetes patients (mikrodiab)

Conditions: Type 2 Diabetes; Cancer

Summary: the purpose of the study is to determine whether glycemic control (hba1c) is linked to chromosomal damage in type 2 diabetes patients


Eligibility criteria:
inclusion criteria: * type 2 diabetes (t2dm) * sex: female * age: \> 30years * medication: oral anti-diabetics and/or insulin therapy * constant nutritional behavior, constant physical activity, constant weight for the last 4 weeks * non-smoking for at least 1 year exclusion criteria: * patients with type 1 dm * age: \< 30years * pregnant or lactating women * participation in another clinical trial * change of medication in regard to metabolic parameters within the last 4 weeks * significant cardiovascular damage with nyha \> iii * liver disease with three-times higher transaminase values * chronic kidney disease with serum creatinine \> 2 mg/dl * dialysis * hiv positive * history of chronic alcohol abuse in the last two years * history of cancer, stroke, organ transplantation * male

Keywords: type 2 diabetes chromosomal damage micronuclei dna damage hba1c comet assay glycemic control
burden of urinary incontinence in home care patients in the state of geneva

Conditions: Urinary Incontinence

Summary: urinary incontinence (ui) is a frequent problem in community-dwelling older adults and has a huge burden on health complications and healthcare costs. although effective treatments exist, ui is frequently neglected resulting in unmet needs for continence treatment and potential negative health outcomes. the impact of ui in older patients receiving home care services has not been extensively explored. in a recent study we observed that ui was identified in 46% of 699 patients followed by the "fondation des services d'aide et de soins à domicile" in geneva but the impact of ui on outcome such as institutionalization, hospitalization or death is unknown.


Eligibility criteria:
inclusion criteria: * between july 2004 and december 2004 * 699 adults patients followed by the "fondation des services d'aide et de soins à domicile" in geneva (two region in the state of geneva: meyrin and st-jean)

Keywords: mortality patient readmission institutionalization
regulation of mucosal healing in inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: the objective of the current study is to compare non-healing colonic ulcers in patients with inflammatory bowel disease (ibd) with iatrogenic colonic ulcers (biopsy sites) in healthy control patients and patients with rheumatoid or psoriatic arthritis. patients will be biopsied at baseline and again at a follow-up visit in a "biopsy of the biopsy" approach. these biopsies will be used to reveal patterns about gene expression and mitochondrial function during ulcer healing.

induction of mucosal healing in inflammatory bowel disease (ibd) is associated with reduced hospitalizations, surgeries, and reduced cancer risk. however, previous studies have shown that 54-69% of ulcerative colitis (uc) patients fail to heal ulcers after several weeks of treatment, and roughly half do not maintain remission at one year. the single most important factor in preventing severe medical consequences, like colon removal surgery or cancer, is treatment to completely heal the top layer of the intestine as quickly as possible. healing is a complex process and the dysfunction observed in colitis can only be fully understood by comparison to healing in non-ibd patients. this is a prospective trial involving three groups of patients: 1) ibd patients with active disease, newly treated with anti-tnf therapy (biologic failure or naïve); 2) non-ibd patients with rheumatoid/psoriatic arthritis who are receiving anti-tnf therapy, and 3) healthy control patients. biopsies will be collected at baseline during standard of care endoscopy and at a follow-up research endoscopy. this study will probe mechanisms of ulcer healing by analyzing gene expression patterns and mitochondrial function.

Eligibility criteria:
inclusion criteria (group 1): * diagnosed ulcerative colitis or crohn's disease * biologic failure or naive to biologic treatment * eligible to be treated with anti-tnf therapy inclusion criteria (group 2): * diagnosed rheumatoid or psoriatic arthritis * receiving anti-tnf antibody therapy at the time of enrollment inclusion criteria (group 3): * endoscopically unremarkable colonic mucosa * absence of inflammatory bowel disease exclusion criteria: * classified in an anesthesia risk group, asa class =4 * history of bleeding diathesis or coagulopathy * stroke or transient neurological attack with the last 6 months * pregnant * receiving anticoagulants or anti-platelet medications other than low-dose aspirin * receiving steroid therapy or metformin * hiv positive * incarceration * history of total proctocolectomy * history of system chemotherapy within 18 months * uncontrolled intercurrent illness

Keywords: mucosal rheumatoid arthritis psoriatic arthritis ulcer colitis crohn's mitochondria biopsy wound biologic anti-tnf
the relationship of orthodontic malocclusions with temporomandibular joint disorders

Conditions: Temporomandibular Joint Disorders

Summary: the patients who applied to the hospital for orthodontic treatment were asked various questions to evaluate their oral health related quality of life, malocclusions and self reported temporomandibular joint problems.

the patients who applied to the hospital for orthodontic treatment were asked various questions to evaluate their oral health related quality of life, malocclusions and self reported temporomandibular joint problems. for this purposes oral health impact profile-14, and helkimo's indexes were used.the relationship between these results were investigated.

Eligibility criteria:
inclusion criteria: * wish to receive orthodontic treatment in our clinic. exclusion criteria: * the absence of willingness for the temporomandibular joint and clinical examination or answering the survey questions.
hip prospective study

Conditions: Hip Arthropathy

Summary: in an evaluation report dated 2014, the has (haute autorité de santé -french national authority for health) highlights that long-term clinical data on hip prostheses are needed in the context of the french healthcare system. in addition, per the european regulation 2017/745, medical devices manufacturers shall conduct post-market clinical follow-up (pmcf) on their devices or provide a justification why pmcf is not applicable. therefore, as part of the pmcf process of their hip prostheses, serf wants to conduct a pmcf investigation to ensure the long-term real-life performance, safety and benefits of these prostheses. hips is a non-comparative, prospective, multicentric, national, 15-year follow-up clinical investigation.


Eligibility criteria:
inclusion criteria: * male or female adults * planned to be implanted with investigational medical devices per the ifus: * implantation in skeletally mature adults (usually aged 60-65 and over), with an extremely painful and/or disabled joint and insufficiently improved by alternative treatment options after an observation period lasting from a few weeks to a few months * implantation of investigational medical devices as integrated systems (all components from serf, no component from another manufacturer) * for an intended purpose and indication listed in the ifus * affiliated to french social security * who provided a dated and signed informed consent form exclusion criteria: * patient protected by a french legal measure * patient not able to express his/her consent as deemed by the investigator * patient deprived of liberty or hospitalized without consent * pregnant or breastfeeding women * patient contraindicated to investigational medical devices implantation per the ifus * patient contraindicated to radiographic follow-up * patient a priori not able to meet the follow-up visits as deemed by the investigator * patient not able to fulfil a self-assessment questionnaire as deemed by the investigator.

Keywords: hip arthropalsty hip prosthesis